Erythropoiesis stimulating agents (ESAs) fix anemia in patients with chronic kidney disease (CKD). Recombinant human erythropoietin (EPO) is one example. Peginesatide , inhibitors of hypoxia-inducible transcription factor, gene therapy, EPO fusion proteins, drugs that inhibit GATA and hematopoietic cell phosphatase are experimental therapies being tested. Anemia management using both iron and/or ESAs is a successful strategy used by clinicians. Intravenous (IV) iron such as Ferumoxytol (Feraheme) and ferric carboxymaltose (Ferinject)do not require a test dose, and a much higher dose of iron can be delivered as a single administration.
Reference:
Curr Opin Investig Drugs. Chronic kidney disease-associated anemia: new remedies. Del Vecchio L, Cavalli A, Tucci B, Locatelli F.
No comments:
Post a Comment